X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
RVU120 is a selective, first-in-class dual CDK8/19 kinase inhibitor. It is being developed for the treatment of patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
Lead Product(s): RVU120
Therapeutic Area: Oncology Product Name: RVU120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2024
Details:
RVU120 is a selective, first-in-class dual CDK8/19 kinase inhibitor. It is being evaluated in phase 2 clinical trials in combination with venetoclax for the treatment of patients with relapsed/refractory AML.
Lead Product(s): RVU120,Venetoclax
Therapeutic Area: Oncology Product Name: RVU120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2024
Details:
RVU120 is a selective CDK8/CDK19 kinase inhibitor with potential for the treatment of hematological malignancies and solid tumors currently in phase I clinical development for the treatment of acute myeloid leukemia and myelodysplastic syndromes.
Lead Product(s): RVU120
Therapeutic Area: Oncology Product Name: RVU120
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2023
Details:
MEN1703 (SEL24) is a first-in-class, dual PIM/FLT3 kinase inhibitor with a unique activity profile, which is investigated for the treatment of diffuse large B-cell lymphoma.
Lead Product(s): MEN1703
Therapeutic Area: Oncology Product Name: MEN1703
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Menarini
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2023
Details:
RVU120 is a selective, first-in-class dual CDK8/CDK19 kinase inhibitor that has shown signs of clinical activity in treated patients, as well as efficacy in numerous in vitro and in vivo models of hematologic malignancies and solid tumors.
Lead Product(s): RVU120
Therapeutic Area: Oncology Product Name: RVU120
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Polpharma
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Agreement July 06, 2023
Details:
RVU120, a selective CDK8/CDK19 kinase inhibitor with potential for the treatment of hematological malignancies and solid tumors, is currently in phase I clinical development for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
Lead Product(s): RVU120
Therapeutic Area: Oncology Product Name: RVU120
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: BioNTech
Deal Size: $57.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 22, 2022
Details:
The global collaboration will consist of two parts: BioNTech will receive a global, exclusive license to develop and commercialize Ryvu’s STING agonist portfolio as standalone small molecules, including as monotherapy and in therapeutic combinations.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: BioNTech
Deal Size: $41.4 million Upfront Cash: $20.7 million
Deal Type: Collaboration November 30, 2022
Details:
RVU120 (SEL120) is a small molecule selective CDK8 kinase inhibitor in clinical development for the treatment of acute myeloid leukemia and high-risk myelodysplastic syndromes, as well as solid tumors.
Lead Product(s): RVU120
Therapeutic Area: Oncology Product Name: SEL120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
Preclinical data demonstrate that treatment with RVU120, a small molecule inhibitor of CDK8/19 kinases, in combination with an anti-CD20 antibody causes upregulation of LAMP1 surface level and increases NK cell cytotoxicity against CD20-positive positive DLBCL cell lines.
Lead Product(s): RVU120
Therapeutic Area: Oncology Product Name: RVU120
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
Ryvu aims to address the clinical limitations of current treatments in oncology and provide patients with access to innovative therapies RVU120, for the treatment of haematologic and solid tumours.
Lead Product(s): RVU120
Therapeutic Area: Oncology Product Name: RVU120
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: European Investment Bank
Deal Size: $21.8 million Upfront Cash: Undisclosed
Deal Type: Financing August 17, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
